We studied patients with pulmonary hypertension who had evidence of bronchial respon-siveness to inhaled albuterol. The records of all patients evaluated for lung transplantation were reviewed: the charts of patients with pulmonary hypertension, either primary (PPH, n=46) or Eisen-menger's syndrome (n=12), were abstracted. Measurements of lung function revealed equal numbers of patients with normal, restrictive, obstructive, and mixed abnormalities. None were more than moderate. Airway responsiveness was defined as an increase of forced expiratory volume in 1 second (FEV1) >15% or forced expiratory flow between 25% and 75% of the vital capacity (FEF25-75) >25%. Of the 24 PPH and nine Eisenmenger's patients, 14 and four, respectively, had reversible airflow obstruction. These patients were more likely to have a history of atopic disease and to have responded to calcium channels blockers during hemodynamic monitoring. They did not have more severe pulmonary hypertension, as measured by hemodynamic monitoring. Four patients had a history of asthma, which required hospitalization in three. Reversible airflow obstruction occurred in half of the patients with pulmonary hypertension and was clinically important in at least three.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223.
3.
3. Sandoval J, Bauerle O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol. 1995; 25:466-475.
4.
4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
5.
5. Becklake M, Crapo R, Buist S, et al. Lung function testing: selection of reference values and interpretive strategies. Am Rev Respir Dis. 1991;144:1202-1218.
6.
6. Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia: WB Saunders Co; 1971.
7.
7. Stoller JK, Basheda S, Laskowski D, et al. Trial of standard versus modified expiration to achieve end-of-test spirometry criteria. Am Rev Respir Dis. 1993;148:275-280.
8.
8. American Thoracic Society. Lung Function Testing: Selection of Reference Values and Interpretative Strategies. Am Rev Respir Dis. 1991;144:1202-1216.
9.
9. Fernandez-Bonetti P, Lupi-Herrera E, Martinez-Guerra ML, et al. Peripheral airways obstruction in idiopathic pulmonary artery hypertension (primary). Chest. 1983;83:732-738.
10.
10. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med. 1992;327:117-119.
11.
11. Giaid A, Yanagisawa D, Langleben D, et al. Expression of endothelin-I in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328:1732-1739.
12.
12. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
13.
13. Eisenberg PR, Lucore C, Kaufman L, et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation. 1990;82: 841-847.
14.
14. Rabinovitch M. Pathopysiology of pulmonary hypertension. In: Emman-ouilides GC, Allen HD, Riemen-schneider TA, Gutgesell HP, eds. Heart Disease in Infants, Children and Adolescents. 5th ed.Baltimore: Williams & Wilkins, 1995:1659-1694.
15.
15. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothe-lin-1 in pulmonary hypertension: marker or mediator of disease?Ann Intern Med. 1991;114:464-469.
16.
16. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Circulation. 1991; 84:2280-2285.
17.
17. Eddahibi S, Raffestin B, Braquet P, et al. Pulmonary vascular reactivity to endothelin-1 in normal and chronically pulmonary hypertensive rats. J Cardiovasc Pharmacol. 1991;17:S358-S361.
18.
18. Uchida Y, Ninomiya H, Saotome M, et al. Endothelin, a novel vasoconstrictor peptide, as a potent bronchoconstrictor. Eur J Pharmacol. 1988;154: 227-228.
19.
19. Turner NC, Power RF, Polak JM, et al. Endothelin-induced contractions of tracheal smooth muscle and identification of specific endothelin binding sites in the trachea of the rat. Br J Pharmacol. 1989;98:361-366.
20.
20. Mattoli S, Mezzetti M, Riva G, et al. Specific binding of endothelin on human bronchial smooth muscle cells in culture and secretion of endothelin-like material from bronchial epithe-lial cells. Am J Respir Cell Mol Biol. 1990; 3:145-151.
21.
21. Glansberg MK, Ergal A, Wanner A, Puett D. Endothelin-1 promotes mitogenesis in airway smooth muscle cells. Am JRespir Cell Mol Biol. 1994;10:316-321.
22.
22. Peacock AJ, Davies KE, Shock A, et al. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol. 1993;7:492-499.
23.
23. Takuwa N, Takuwa Y, Yanagisawa M, et al. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol turnover in Swiss 3T3 fibroblasts. J Biol Chem. 1989; 264: 7856-7861.
24.
24. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum. 1991;34:478-483.
25.
25. Springall DR, Howarth PH, Counihan H, et al. Endothelin immunoreactivity of airway epithelium in asthmatic patients. Lancet. 1991;337:697-701.
26.
26. Vittori E, Marini M, Fasoli A, et al. Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids. Am Rev Respir Dis. 1992; 146:1320-1325.
27.
27. Redington AE, Springall DR, Ghatei MA, et al. Endothelin in bronchoalveolar lavage fluid and its relation to airflow obstruction in asthma. Am J Respir Crit Care Med. 1994;151:1034-1039.
28.
28. Aoki T, Kojima T, Ono A, et al. Circulating ET-1 levels in patients with bronchial asthma. Ann Allergy. 1994; 73:365-369.
29.
29. Liu SF, Crawley DE, Barnes PJ, Evans TW. Endothelium-derived nitric oxide inhibits pulmonary vasoconstriction in isolated blood perfused rat lungs. Am Rev Respir Dis. 1991;143:32-37.
30.
30. Persson MG, Gustafsson LE, Wiklund NP, et al. Endogenous nitric oxide as a probable modulator of pulmonary circulation and hypoxic pressor response in vivo. Acta Physiol Scand. 1990;140:449-457.
31.
31. Adnot S, Raffestin B, Eddamibi S, et al. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest. 1991;87:155-162.
32.
32. Pepke-Zaba J, Higenbottam T, Dinh-Xuan A, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
33.
33. Roberts JD, Polaner DH, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary circulation of the newborn. Lancet. 1992;340:818-819.
34.
34. Hogman M, Frostell C, Amberg H, Hedenstierna G. Inhalation of nitric oxide modulates methacholine-induced bronchoconstriction in the rabbit. Eur Respirj. 1993;6;177-180.
35.
35. Frostell C, Hogman M, Hedenstrom H, Hedenstierna G. Is nitric oxide inhalation beneficial to the asthmatic patient?Am Rev Respir Dis. 1993; 147:A515-A515.
36.
36. Belvisi MG, Stretton CD, Barnes PJ. Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in human airways. Eur J Pharmacol. 1992;210:221-222.
37.
37. Bai TR, Bramley AM. Effects of an inhibitor of nitric oxide synthase on neural relaxation in human bronchi. Am J Physiol1993;8:425-430.
